Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months (Q42248061)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 December 2013

Language	Label	Description	Also known as
English	Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months	scientific article published on 16 December 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

human papillomavirus 16

1 reference

based on heuristic

inferred from title

Jorge Salmerón

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

3

object named as

Nubia Muñoz

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Margaret Stanley

2

object named as

Margaret Stanley

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mauricio Hernández-Ávila

9

object named as

Mauricio Hernández-Ávila

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Aurelio Cruz-Valdez

5

object named as

Aurelio Cruz-Valdez

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Rolando Herrero

8

object named as

Rolando Herrero

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Eduardo Cesar Lazcano-Ponce

1

object named as

Eduardo Lazcano-Ponce

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Leticia Torres

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Rosalba Rojas

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

0 references

publication date

16 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

725-732

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24355090%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

New paradigms and challenges in cervical cancer prevention and control in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Two doses of HPV vaccine may be sufficient

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

[Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens inCervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Sense and the science of childhood immunization: can we achieve more with less?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.059

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42248061&oldid=1940090460"